2025
Chemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in triple negative breast cancer (TNBC).
Gandhi S, Deshmukh S, Wu S, Xiu J, Lesinski G, Paulos C, Czerniecki B, Chalasani P, Yao S, Ernstoff M, Chumsri S, Trapani D, Leone J, Lustberg M, Sledge G, Kalinsky K, Kalinski P. Chemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1106-1106. DOI: 10.1200/jco.2025.43.16_suppl.1106.Peer-Reviewed Original ResearchTriple negative breast cancerImmune checkpoint inhibitorsTumor mutational burdenTumor microenvironmentCXCR3 expressionBreast cancerHER2+Overall survivalPredictive biomarkersHigher expression of immune checkpoint genesExpression of immune checkpoint genesImmune checkpoint inhibitor pembrolizumabT cell inflamed scoreImmune checkpoint inhibitor efficacyAssociated with longer survivalReal-world overall survivalCognate receptor CXCR3Enhance ICI efficacyPD-L1 positivityT cell infiltrationImmune checkpoint genesAggressive breast cancerNegative breast cancerTumor microenvironment characteristicsImmune cell fractions
2024
Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.
Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.Peer-Reviewed Original ResearchNon-small cell lung cancerDiagnosis of LMNational Comprehensive Cancer NetworkLeptomeningeal metastasesTumor cell assayPositive CTCsCerebrospinal fluidData cutoffOverall survivalNeurological symptomsAssessment of circulating tumor DNASensitivity of tumor cell detectionCTC assayManagement of leptomeningeal metastasisTime of data cutoffDiagnosis of leptomeningeal metastasisAssociated with longer survivalMedian overall survivalOmmaya reservoir placementEnumeration of circulating tumor cellsNegative cytology resultsCell lung cancerEffective treatment optionProgressive neurological symptomsInitiation of treatment
2020
DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability
Tanaka A, Wang J, Shia J, Zhou Y, Ogawa M, Hendrickson R, Klimstra D, Roehrl M. DEAD-box RNA helicase protein DDX21 as a prognosis marker for early stage colorectal cancer with microsatellite instability. Scientific Reports 2020, 10: 22085. PMID: 33328538, PMCID: PMC7745018, DOI: 10.1038/s41598-020-79049-9.Peer-Reviewed Original ResearchConceptsStage colorectal cancerLate stage colorectal cancerEarly stage colorectal cancerColorectal cancerProtein expressionMicrosatellite instabilityAssociated with longer survivalDisease-free survivalTumor cell nucleiKaplan-Meier analysisColorectal cancer casesNon-mucinous histologyPatient clinical outcomesColorectal cancer cohortEarly stage cancerMismatch repair statusTumor gradeTumor locationBenign mucosaCancer immunityClinicopathological featuresPrognostic markerClinical outcomesLonger survivalCancer cases
2017
Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer
Galsky M, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao C, Sfakianos J, Mehrazin R, Waingankar N, Oh W, Mazumdar M, Ferket B. Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-12. PMID: 30657403, PMCID: PMC6874030, DOI: 10.1200/cci.17.00116.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerEffect of neoadjuvant chemotherapyNeoadjuvant chemotherapyMuscle-invasive bladder cancer treated with cystectomyHazard ratioBladder cancerFacility-level variablesTreatment of muscle-invasive bladder cancerUS life tablesInternal-external cross-validationDeath riskAssociated with shorter survivalPilot usability testingAssociated with longer survivalBladder cancer-specificClinical T stageMedian overall survivalNeoadjuvant chemotherapy useWeb-based toolOther-cause mortalityAbsolute risk reductionHigh-volume facilitiesIndividualized survival estimatesOverall survivalT stageA Web-Based Tool to Facilitate Shared Decision-Making Regarding Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer
Galsky M, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Ramireddy K, Hu L, Tsao C, Sfakianos J, Mehrazin R, Hassanzadeh N, Waingankar N, Oh W, Kohli A, Otobo E, Mazumdar M, Ferket B. A Web-Based Tool to Facilitate Shared Decision-Making Regarding Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. Iproceedings 2017, 3: e43. DOI: 10.2196/iproc.8456.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerEffect of neoadjuvant chemotherapyNeoadjuvant chemotherapyBladder cancerHazard ratioMuscle-invasive bladder cancer treated with cystectomyPelvic lymph node dissectionPatients treated with cystectomyAssociated with shorter survivalAssociated with longer survivalBladder cancer-specificClinical T stageNeoadjuvant chemotherapy useLymph node dissectionNational Cancer DatabaseTreated with cystectomyUrothelial bladder cancerHigher comorbidity indexTime of diagnosisPopulation-based studyWeb-based appIndividual patient outcomesMetastatic recurrenceMicrometastatic diseaseNode dissection
2015
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone
Konstantinidis I, Groot Koerkamp B, Do R, Gönen M, Fong Y, Allen P, D'Angelica M, Kingham T, DeMatteo R, Klimstra D, Kemeny N, Jarnagin W. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2015, 122: 758-765. PMID: 26695839, PMCID: PMC4764409, DOI: 10.1002/cncr.29824.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsBile Ducts, IntrahepaticCamptothecinCholangiocarcinomaDeoxycytidineDisease-Free SurvivalFemaleFloxuridineFluorouracilGemcitabineHepatic ArteryHumansInfusions, Intra-ArterialIrinotecanMaleMiddle AgedMitomycinRetrospective StudiesSurvival RateConceptsHepatic arterial infusionHepatic arterial infusion chemotherapySystemic chemotherapyIntrahepatic cholangiocarcinomaOverall survivalUnresectable tumorsPatients treated with systemic chemotherapyCombination groupCombination of systemic chemotherapyMemorial Sloan Kettering Cancer CenterAssociated with longer survivalAssociated with poor survivalMedian overall survivalUnresectable intrahepatic cholangiocarcinomaArterial infusion chemotherapyLymph node diseaseOutcomes of patientsLog-rank testKaplan-Meier analysisAssociated with greater survivalComplete resectionInfusion chemotherapyConsecutive patientsNode diseaseArterial infusion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply